HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered β-catenin switch

Molecular Endocrinology

Volumn 27, Issue 2, 2013, Pages 325-335

  Jin, Zixue ^a   Wei, Wei ^a   Dechow, Paul C ^b   Wan, Yihong ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; HISTONE DEACETYLASE 7; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MASS; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; BETA CATENIN; BONE AND BONES; BONE DENSITY; BONE REMODELING; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CYCLIN D1; DOWN-REGULATION; HISTONE DEACETYLASES; MICE; MICE, KNOCKOUT; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOPOROSIS; RANK LIGAND;

EID: 84873019253     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1302     Document Type: Article

References (42)

1. Bruzzaniti A, Baron R 2006 Molecular regulation of osteoclast activity. Rev Endocr Metab Disord 7:123-139
2. Novack DV, Teitelbaum SL 2008 The osteoclast: friend or foe? Annu Rev Pathol 3:457-484
3. Wan Y 2010 PPARγ in bone homeostasis. Trends Endocrinol Metab 21:722-728
4. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 c-Fos: a key regulator of osteoclastmacrophage lineage determination and bone remodeling. Science 266:443-448
5. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T 2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901
6. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G 2007 Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156-163
7. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC 2009 Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371-379
8. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2009 Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588
9. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C 2010 Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948-959
10. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J 2005 Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844
11. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy Jr JD 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494.
12. Day TF, Guo X, Garrett-Beal L, Yang Y 2005 Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739-750
13. Glass II DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G 2005 Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764
14. Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C 2005 Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8:727-738
15. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO 2005 Essential role of β-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168
16. Wei W, Zeve D, Suh JM, Wang X, Du Y, Zerwekh JE, Dechow PC, Graff JM, Wan Y 2011 Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol 31:4706-4719
17. Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H, Colonna M 2012 TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol 188:2612-2621
18. Haberland M, Montgomery RL, Olson EN 2009 The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32-42
19. McGee-Lawrence ME, Westendorf JJ 2011 Histone deacetylases in skeletal development and bone mass maintenance. Gene 474:1-11
20. Cantley MD, Fairlie DP, Bartold PM, Rainsford KD, Le GT, Lucke AJ, Holding CA, Haynes DR 2011 Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J Cell Physiol 226:3233-3241
21. Kim HN, Lee JH, Jin WJ, Ko S, Jung K, Ha H, Lee ZH 2012 MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice. Eur J Pharmacol 691:69-76
22. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, Hotokebuchi T, Kohashi O, Kukita A 2005 Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production. J Immunol 175:5809-5816
23. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O 2003 Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 101:3451-3459
24. Williams PJ, Nishu K, Rahman MM 2011 HDAC inhibitor trichostatin A suppresses osteoclastogenesis by upregulating the expression of C/EBP-β and MKP-1. Ann NY Acad Sci 1240:18-25
25. Johnstone RW 2002 Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299
26. Kazantsev AG, Thompson LM 2008 Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7:854-868
27. Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R, Westendorf JJ 2008 Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res 23:361-372
28. Pham L, Kaiser B, Romsa A, Schwarz T, Gopalakrishnan R, Jensen ED, Mansky KC 2011 HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. J Biol Chem 286:12056-12065
29. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN 2006 Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126:321-334
30. Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE, Tallquist MD, Graff JM 2008 White fat progenitor cells reside in the adipose vasculature. Science 322:583-586
31. Wei W, Zeve D, Wang X, Du Y, Tang W, Dechow PC, Graff JM, Wan Y 2011 Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population. Mol Cell Biol 31:4692-4705
32. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I 1999 Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8:265-277
33. Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R, Mohammadi M, Gerard RD, Dechow PC, Mangelsdorf DJ, Kliewer SA, Wan Y 2012 Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferatoractivated receptor γ. Proc Natl Acad Sci USA 109:3143-3148
34. Wei W, Wang X, Yang M, Smith LC, Dechow PC, Sonoda J, Evans RM, Wan Y 2010 PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 11:503-516
35. Wan Y, Chong LW, Evans RM 2007 PPAR-γ regulates osteoclastogenesis in mice. Nat Med 13:1496-1503
36. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, Ross FP, Teitelbaum SL 2008 NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem 283:6509-6518
37. Mihaylova MM, Vasquez DS, Ravnskjaer K, Denechaud PD, Yu RT, Alvarez JG, Downes M, Evans RM, Montminy M, Shaw RJ 2011 Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145:607-621
38. Wang B, Moya N, Niessen S, Hoover H, Mihaylova MM, Shaw RJ, Yates III JR, Fischer WH, Thomas JB, Montminy M 2011 A hormone-dependent module regulating energy balance. Cell 145:596-606
39. Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE 2012 Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP. 3 randomised controlled trial. Lancet Oncol 13:275-284
40. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ 2009 Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135
41. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
42. Baron R, Ferrari S, Russell RG 2011 Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677-692